Skip to main content

Articles

FDA Approvals, Payers' Guide
Farydak (Panobinostat): First HDAC Inhibitor Approved for Patients with Relapsed Multiple Myeloma
Read More
FDA Approvals, Payers' Guide
Fycompa (Perampanel Hydrate) Receives Expanded Indication for Primary Generalized Tonic-Clonic Seizures
Read More
FDA Approvals, Payers' Guide
Imbruvica (Ibrutinib): First Drug Approved for the Treatment of Patients with Waldenström’s Macroglobulinemia
Read More
FDA Approvals, Payers' Guide
Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
Read More
FDA Approvals, Payers' Guide
Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer
Read More
FDA Approvals, Payers' Guide
Ninlaro (Ixazomib): First Oral Proteasome Inhibitor Approved for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Read More
FDA Approvals, Payers' Guide
Nucala (Mepolizumab): First IL-5 Antagonist Monoclonal Antibody FDA Approved for Maintenance Treatment of Patients with Severe Asthma
Read More
FDA Approvals, Payers' Guide
Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma
Read More
FDA Approvals, Payers' Guide
Portrazza (Necitumumab), an IgG1 Monoclonal Antibody, FDA Approved for Advanced Squamous Non–Small-Cell Lung Cancer
Read More
FDA Approvals, Payers' Guide
Praluent (Alirocumab): First PCSK9 Inhibitor Approved by the FDA for Hypercholesterolemia
Read More
Page 116 of 245
Results 1151 - 1160 of 2441